CLOVER BIO-B (02197) opened significantly higher by over 5%. As of press time, the stock was up 5.67% to HK$2.98, with a trading volume of HK$1.3738 million.

On the news front, Clover Biopharmaceuticals announced positive preliminary data from two ongoing clinical trials, including:

A Phase I clinical trial conducted in Australia to evaluate respiratory combination vaccine candidates SCB-1022 and SCB-1033 in a head-to-head comparison with SCB-1019, targeting elderly populations who had not previously received any RSV vaccines; and a Phase I clinical trial conducted in the United States for a head-to-head evaluation of repeat vaccination with SCB-1019 versus AREXVY, targeting elderly populations who had received their first AREXVY vaccination at least two influenza seasons prior to enrollment.

Based on these positive Phase I clinical trial results, Clover Biopharmaceuticals plans to advance SCB-1022 and SCB-1033 to Phase II clinical trials in the first half of 2026.